TPP Matches Chinese Pharma & Capital With Western Assets
Executive Summary
Finding the right partner to enter the Chinese pharma market or access Chinese capital is not a trivial exercise for Western companies. Speaking at the 2018 Biotech Showcase, Tony Chu, founder and managing partner of TPP Healthcare, told Scrip that the advisory company was established to help Western companies achieve their Chinese goals. The sweet spot is late-stage assets for joint venturing or cash thirsty biotechs with programs focused on Asia Pacific health challenges.
You may also be interested in...
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Despite BMS Bid, Celgene Pays $75m Upfront For Immatics Assets Options
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.